BACKGROUND: Nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy provides sufficient conditions for progressive subcutaneous fat wasting in HIV-infected patients. As NRTI-induced host toxicity is proposed to involve cellular mitochondrial DNA (mtDNA) depletion, determinants of cellular mtDNA copy number and mitochondrial mass in adipocyte samples from NRTI-treated HIV-infected patients and antiretroviral-naive controls were investigated. Adipose tissue morphology was also assessed. METHODS: Subcutaneous fat samples were obtained from NRTI-treated, HIV-infected patients (n = 21), antiretroviral therapy-naive HIV-infected controls (n = 11), and HIV-seronegative controls (n = 6). Non-adipocytes were removed by collagenase digestion. Adipocyte mtDNA copies/cell was measured using a real time PCR-based assay, and adipocyte mitochondrial protein content was also measured. Light and electron microscopy were performed on tissue samples. FINDINGS: Adipocyte mtDNA copies/cell values were similar (P = 0.56) in HIV seronegative and HIV-infected control groups. NRTI treatment was associated with reduced adipocyte mtDNA copies/cell, representing mean mtDNA depletion in NRTI-treated individuals of 77.7% compared with the mean value for the HIV-infected control group (P < 0001). Additionally, significant differences were found in adipocyte mtDNA copies/cell between patients receiving stavudine (n = 12, mean mtDNA depletion 87.1%) and zidovudine (n = 9, mean mtDNA depletion 52.1%) (P < 0.001). Adipocyte mitochondrial mass was increased in the stavudine group only (mean increase 289%, P < 0.01). INTERPRETATION: NRTI therapy is associated with mtDNA depletion and mitochondrial proliferation in adipocytes, consistent with the hypothesis that NRTI-induced mtDNA depletion contributes to the pathogenesis of subcutaneous fat wasting. Morphologic assessment also supports a role for NRTI therapy in inducing adipocyte metabolic dysfunction and cell death.
BACKGROUND: Nucleoside analogue reverse transcriptase inhibitor (NRTI) therapy provides sufficient conditions for progressive subcutaneous fat wasting in HIV-infectedpatients. As NRTI-induced host toxicity is proposed to involve cellular mitochondrial DNA (mtDNA) depletion, determinants of cellular mtDNA copy number and mitochondrial mass in adipocyte samples from NRTI-treated HIV-infectedpatients and antiretroviral-naive controls were investigated. Adipose tissue morphology was also assessed. METHODS: Subcutaneous fat samples were obtained from NRTI-treated, HIV-infectedpatients (n = 21), antiretroviral therapy-naive HIV-infected controls (n = 11), and HIV-seronegative controls (n = 6). Non-adipocytes were removed by collagenase digestion. Adipocyte mtDNA copies/cell was measured using a real time PCR-based assay, and adipocyte mitochondrial protein content was also measured. Light and electron microscopy were performed on tissue samples. FINDINGS: Adipocyte mtDNA copies/cell values were similar (P = 0.56) in HIV seronegative and HIV-infected control groups. NRTI treatment was associated with reduced adipocyte mtDNA copies/cell, representing mean mtDNA depletion in NRTI-treated individuals of 77.7% compared with the mean value for the HIV-infected control group (P < 0001). Additionally, significant differences were found in adipocyte mtDNA copies/cell between patients receiving stavudine (n = 12, mean mtDNA depletion 87.1%) and zidovudine (n = 9, mean mtDNA depletion 52.1%) (P < 0.001). Adipocyte mitochondrial mass was increased in the stavudine group only (mean increase 289%, P < 0.01). INTERPRETATION: NRTI therapy is associated with mtDNA depletion and mitochondrial proliferation in adipocytes, consistent with the hypothesis that NRTI-induced mtDNA depletion contributes to the pathogenesis of subcutaneous fat wasting. Morphologic assessment also supports a role for NRTI therapy in inducing adipocyte metabolic dysfunction and cell death.
Authors: L Egaña-Gorroño; E Martínez; P Domingo; M Loncà; T Escribà; J Fontdevila; F Vidal; E Negredo; J M Gatell; M Arnedo Journal: Antimicrob Agents Chemother Date: 2014-08-25 Impact factor: 5.191
Authors: Amy Fleischman; Stine Johnsen; David M Systrom; Mirko Hrovat; Christian T Farrar; Walter Frontera; Kathleen Fitch; Bijoy J Thomas; Martin Torriani; Hélène C F Côté; Steven K Grinspoon Journal: Am J Physiol Endocrinol Metab Date: 2007-02-06 Impact factor: 4.310
Authors: Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich Journal: AIDS Res Hum Retroviruses Date: 2008-10 Impact factor: 2.205
Authors: Caryn G Morse; Joachim G Voss; Goran Rakocevic; Mary McLaughlin; Carol L Vinton; Charles Huber; Xiaojun Hu; Jun Yang; Da Wei Huang; Carolea Logun; Robert L Danner; Zoila G Rangel; Peter J Munson; Jan M Orenstein; Elisabeth J Rushing; Richard A Lempicki; Marinos C Dalakas; Joseph A Kovacs Journal: J Infect Dis Date: 2012-04-03 Impact factor: 5.226
Authors: Joachim G Voss; Adrian Dobra; Caryn Morse; Joseph A Kovacs; Robert L Danner; Peter J Munson; Carolea Logan; Zoila Rangel; Joseph W Adelsberger; Mary McLaughlin; Larry D Adams; Raghavan Raju; Marinos C Dalakas Journal: Biol Res Nurs Date: 2013-01-16 Impact factor: 2.522
Authors: Cecilia M Shikuma; Louie Mar A Gangcuangco; Deirdre A Killebrew; Daniel E Libutti; Dominic C Chow; Beau K Nakamoto; Chin Yuan Liang; Cris I P Milne; Lishomwa C Ndhlovu; Jason D Barbour; Bruce T Shiramizu; Mariana Gerschenson Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731